Document Detail

Interventions for non-oliguric hyperkalaemia in preterm neonates.
MedLine Citation:
PMID:  22592703     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Non-oliguric hyperkalaemia of the newborn is defined as a plasma potassium level > 6.5 mmol/L in the absence of acute renal failure. Hyperkalaemia is a common complication in the first 48 hours of life in very low birth weight (VLBW) (birth weight < 1500 g) and/or very preterm newborns (≤32 weeks gestational age).
OBJECTIVES: To determine the effectiveness and safety of interventions for non-oliguric hyperkalaemia [for the purpose of this review defined as serum potassium > 6.0 mmol/L (the clinical setting in which interventions would likely be introduced prior to reaching a grossly abnormal level) and urine output > 0.5 ml/kg/hour] in preterm or VLBW infants during their first 72 hours of life.
SEARCH METHODS: The Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, Issue 2, 2006) was searched to identify relevant randomised and quasi-randomised controlled trials. The following data bases were searched in June 2006; MEDLINE from 1966, EMBASE from 1980, CINAHL from 1982. Search updated in June 2011.
SELECTION CRITERIA: Randomised or quasi-randomised controlled trials conducted in preterm and/or VLBW neonates with a diagnosis of non-oliguric hyperkalaemia. Interventions included were those aimed at redistributing serum potassium (sodium bicarbonate or insulin and glucose) or increasing the elimination of potassium from the body [diuretics (any type) or ion exchange resins (any type), or exchange transfusion, or peritoneal dialysis, or salbutamol, or albuterol] or counteracting potential arrhythmias from hyperkalaemia (calcium) versus placebo or no intervention; or comparing any two of these interventions. Primary outcome measure was 'All cause mortality during initial hospital stay'. Secondary outcomes included common adverse outcomes seen in preterm infants.
DATA COLLECTION AND ANALYSIS: We used the standard review methods of the Cochrane Neonatal Review Group. Two authors assessed all studies identified as potentially relevant by the literature search for inclusion in the review. Statistical methods included relative risk (RR), risk difference (RD), number needed to treat to benefit (NNTB) or number needed to treat to harm (NNTH) for dichotomous and weighted mean difference (WMD) for continuous outcomes reported with 95% confidence intervals (CI). We used a fixed effect model for meta-analysis. Heterogeneity was assessed using the I squared (I(2) ) statistic.
MAIN RESULTS: Three randomised trials, enrolling 74 preterm infants (outcome data available on 71 infants) evaluated interventions for hyperkalaemia. Urine output was ascertained in only one study (Hu 1999). In none of the trials could we ascertain that allocation to the comparison groups was concealed. The sample sizes of the three trials were very small with 12 (Malone 1991), 19 (Singh 2002) and 40 infants enrolled (Hu 1999). The intervention and the outcome assessments could not be blinded to the clinical staff in two trials (Malone 1991; Hu 1999).One study (Malone 1991), glucose and insulin, compared to cation-exchange resin, caused a reduction in all cause mortality that was of borderline statistical significance: RR 0.18 (95% CI 0.03 to 1.15); RD -0.66 (95% CI -1.09 to -0.22); NNTB 2 (95% CI 1 to 5)]. In the study of Hu (Hu 1999), the incidence of intraventricular haemorrhage ≥ grade 2 was significantly reduced [RR 0.30 (95% CI 0.10 to 0.93); RD -0.35 (95% CI -0.62 to -0.08); NNTB 3 (95% CI 2 to 13).Albuterol inhalation versus saline inhalation changed serum K+ from baseline at four hours [WMD -0.69 mmol/L (95% CI -0.87 to -0.51)] and at eight hours [WMD -0.59 mmol/L (95% CI -0.78 to -0.40)] after initiation of treatment. No differences noted in mortality or other clinical outcomes (Singh 2002).No serious side effects were noted with either the combination of insulin and glucose or albuterol inhalation. Other interventions listed in our objectives have not been studied to date.
AUTHORS' CONCLUSIONS: In view of the limited information from small studies of uncertain quality, no firm recommendations for clinical practice can be made. It appears that the combination of insulin and glucose is preferred over treatment with rectal cation-resin for hyperkalaemia in preterm infants. Both the combination of insulin and glucose and albuterol inhalation deserve further study. The two interventions could possibly be tested against each other. The effectiveness of other potentially effective interventions for non-oliguric hyperkalaemia (diuretics, exchange transfusion, peritoneal dialysis and calcium) have not been tested in randomised controlled trials.
Prakash Vemgal; Arne Ohlsson
Related Documents :
16092323 - A five-year review of childhood mortality at the university college hospital, ibadan.
22048043 - Neurologic outcomes in very preterm infants undergoing surgery.
23118703 - Clinical management of infants and children with gastroesophageal reflux disease.
Publication Detail:
Type:  Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review     Date:  2012-05-16
Journal Detail:
Title:  The Cochrane database of systematic reviews     Volume:  5     ISSN:  1469-493X     ISO Abbreviation:  Cochrane Database Syst Rev     Publication Date:  2012  
Date Detail:
Created Date:  2012-05-17     Completed Date:  2012-08-01     Revised Date:  2013-06-28    
Medline Journal Info:
Nlm Unique ID:  100909747     Medline TA:  Cochrane Database Syst Rev     Country:  England    
Other Details:
Languages:  eng     Pagination:  CD005257     Citation Subset:  IM    
Department of Pediatrics, Fortis Hospital, Bangalore, India.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Albuterol / therapeutic use
Glucose / therapeutic use
Hyperkalemia / therapy*
Infant, Newborn
Infant, Premature
Infant, Premature, Diseases / therapy*
Infant, Very Low Birth Weight
Insulin / therapeutic use
Polystyrenes / therapeutic use
Potassium / blood
Randomized Controlled Trials as Topic
Reference Values
Reg. No./Substance:
0/Insulin; 0/Polystyrenes; 18559-94-9/Albuterol; 28210-41-5/polystyrene sulfonic acid; 50-99-7/Glucose; 7440-09-7/Potassium
Update Of:
Cochrane Database Syst Rev. 2007;(1):CD005257   [PMID:  17253550 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Acupuncture for treatment of irritable bowel syndrome.
Next Document:  Recompression and adjunctive therapy for decompression illness.